Welcome to our dedicated page for CytoMed Therapeutics Ordinary Shares news (Ticker: $GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CytoMed Therapeutics Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CytoMed Therapeutics Ordinary Shares's position in the market.
Rhea-AI Summary
CytoMed Therapeutics (NASDAQ:GDTC) partners with Sengkang General Hospital for a research collaboration on cartilage regeneration therapy using umbilical cord-derived stem cells. The therapy aims to undergo a Phase I clinical trial in Singapore within two years, leveraging the unique advantages of UC-MSCs for regenerative medicine and immune-related disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
-
Rhea-AI Summary
CytoMed Therapeutics (NASDAQ: GDTC) launches a pilot program to isolate and store PBMCs for loyal shareholders, aiming to develop allogeneic cellular therapies. The program offers storage of up to 10 vials of PBMCs for 10 years, free scientific consultations, and discounted immunotherapy treatments. CytoMed encourages shareholders to bank their PBMCs early to ensure quality and usability for future therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.63%
Tags
-
Rhea-AI Summary
CytoMed Therapeutics Limited (NASDAQ: GDTC) has entered into a Research Collaboration Agreement with Sengkang General Hospital to develop a cartilage regeneration therapy using umbilical cord-derived stem cells. The therapy aims to treat cartilage injury and osteoarthritis of the knee, pioneering stem cell use for regenerative medicine in Singapore.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
Rhea-AI Summary
CytoMed Therapeutics Limited (NASDAQ: GDTC) has been granted exclusive rights to a Malaysia, US, and China patent for its chimeric antigen receptor gamma delta T cell technology, targeting solid and hematological tumors. The company's patent portfolio also includes technology for the treatment of various cancers using allogeneic CAR-γδ T cells and an induced pluripotent stem cell-based technology to derive synthetic hybrid gamma delta natural killer T cells. CytoMed has submitted a drug master file to the US FDA for an investigational new drug filing to treat hematological and solid cancers using allogeneic γδ T cells.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
-
Rhea-AI Summary
CytoMed Therapeutics Limited (NASDAQ: GDTC) has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited and a Memorandum of Understanding (MOU) with BioNex Solutions Inc. to explore the potential application of its proprietary allogeneic gamma delta T cells in the treatment of various cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
-
Rhea-AI Summary
CytoMed Therapeutics Limited (NASDAQ: GDTC) announces first half of 2023 financial results and clinical updates, including Phase I clinical trial approval and financial figures. The company aims to develop allogeneic immunotherapies for cancer treatment, focusing on off-the-shelf cellular therapies. They have received patents for their technologies in the US, China, and Japan, and have raised significant gross proceeds from their IPO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.6%
Tags
Rhea-AI Summary
CytoMed Therapeutics Limited (NASDAQ: GDTC) to Present at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference in New York City
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Summary
CytoMed Therapeutics Limited, a Singapore biopharmaceutical company, has been granted a patent by the China National Intellectual Property Administration for its induced pluripotent stem cell (iPSC)-based technology. The patent covers the tech to derive synthetic γδ NKT cells for cancer treatment. CytoMed can generate novel types of synthetic hybrid immune cells without genetic modification or viral vectors, making it a potential 'off-the-shelf' cell therapy. The company also holds patents in the US and China for its licensed allogeneic chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
-
Rhea-AI Summary
CytoMed Therapeutics announces grant of patent for iPSC-based technology in China
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.61%
Tags
Rhea-AI Summary
CytoMed Therapeutics enters into MOU with Hangzhou CNK Therapeutics to utilize PiggyBac technology for gene editing in immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
CytoMed Therapeutics Limited Ordinary Shares
Nasdaq:GDTC
GDTC Rankings
GDTC Stock Data
23.66M
1.69M
70.8%
0.08%
0.31%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
Singapore
About GDTC
incorporated in 2018, cytomed therapeutics is a spin-off from singapore’s agency for science, technology and research ( a*star) and focuses on translating its patented technologies into gamma delta (γδ) t cell- and natural killer (nk) cell-based “off-the-shelf” immunotherapeutics for a wide range of cancers. we also engage in generating induced pluripotent stem cells (ipscs) and translating them into “off-the-shelf” cellular therapeutics using our proprietary technologies for our customers.